Oleandrin Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Cardenolide glycoside compound Reference needs_revision Best effort · source review pending

Also known as: Foliandrin, Neriolin, Folinerin, Corrigen, Neriol, Neriostene

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Solubility

Described in authoritative literature as lipid-soluble or highly fat-soluble. A reliable quantitative aqueous-solubility value was not established in the sources reviewed.

Best-Effort Research Profile

Oleandrin is a steroidal cardenolide glycoside consisting of oleandrigenin glycosylated with a deoxy-methylated hexose. Authoritative chemical databases classify it as a cardenolide glycoside and steroid saponin. NCI describes oleandrin as a lipid-soluble cardiac glycoside with reported preclinical antineoplastic activity through interaction with Na+/K+-ATPase subunits. It is also a toxic constituent associated with the cardiotoxicity of Nerium oleander.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

In mice, reported elimination half-life was 2.3 ± 0.5 hours after oral administration and 0.4 ± 0.1 hours after intravenous administration. These values are animal-study results and should not be generalized to humans.

Onset

In mice, oral dosing produced a reported plasma Cmax at approximately 20 minutes, indicating rapid absorption under the study conditions.

Administration Routes (Research)

oralintravenousintraperitoneal

Reported Research Effects

Inhibits Na+/K+-ATPase activity through cardiac-glycoside interaction with pump subunits.
Preclinical studies report cytotoxic and pro-apoptotic effects in selected cancer-cell and animal models.
Exposure to oleandrin or oleander-derived cardiac glycosides can produce severe cardiovascular, gastrointestinal, and neurologic toxicity; cardiotoxicity is a major research concern.

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Reference pharmacokinetic study in mice used 40 micrograms/kg intravenously and 80 micrograms/kg orally; oral bioavailability was reported as approximately 30% in that study. An additional intraperitoneal brain-distribution experiment used 3 mg/kg oleandrin or 700 mg/kg oleander extract. These are experimental animal-study parameters, not recommended human regimens. The systematic literature review identified limited human pharmacokinetic evidence and emphasized substantial toxicological uncertainty. No standardized scientific reference package sizes were identified; commonSizes is therefore left empty.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN 465-16-7; PubChem CID 11541511; ChEBI CHEBI:59030; molecular formula C32H48O9; molecular weight 576.7 g/mol; InChIKey JLPDBLFIVFSOCC-XYXFTTADSA-N

Source-Backed Observations

Oleandrin has a narrow toxicological margin and cardiac glycoside activity. Human pharmacokinetic evidence is limited. In a murine pharmacokinetic study, oleandrin was rapidly absorbed after oral administration, with a reported plasma Cmax at 20 minutes. Oleandrigenin was identified as a metabolite, and tissue distribution included liver, heart, kidney, and brain under the study conditions.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

Oleandrin | PubChem Compound Summary
https://pubchem.ncbi.nlm.nih.gov/compound/Oleandrin (accessed 2026-09-12)

Oleandrin | NCI Drug Dictionary
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oleandrin (accessed 2026-09-12)

Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander
https://pubmed.ncbi.nlm.nih.gov/12416031/ (accessed 2026-09-12)

Oleandrin: A Systematic Review of its Natural Sources, Structural Properties, Detection Methods, Pharmacokinetics and Toxicology
https://pmc.ncbi.nlm.nih.gov/articles/PMC8902680/ (accessed 2026-09-12)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.